STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
Constantia Pantelidou(Dana-Farber Cancer Institute), Geoffrey I. Shapiro(Brigham and Women's Hospital)
Cited by 33
Related Papers
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
|Blood|2012|297
A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck
|Clinical Cancer Research|2004|67
Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in<i>KRAS</i>-mutant non-small cell lung cancer
|Oncotarget|2018|54
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11
|Oncotarget|2016|22
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in <i>BRCA</i> -associated breast cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2021|5